The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The price of Charles River Laboratories International Inc. (NYSE: CRL) closed at $192.90 in the last session, down -3.85% from day before closing price of $200.62. In other words, the price has decreased by -$3.85 from its previous closing price. On the day, 1.04 million shares were traded. CRL stock price reached its highest trading level at $200.9 during the session, while it also had its lowest trading level at $190.7162.
Ratios:
We take a closer look at CRL’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 55.47 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.45. For the most recent quarter (mrq), Quick Ratio is recorded 1.21 and its Current Ratio is at 1.58. In the meantime, Its Debt-to-Equity ratio is 0.76 whereas as Long-Term Debt/Eq ratio is at 0.76.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Robert W. Baird on August 08, 2024, Downgraded its rating to Neutral and sets its target price to $191 from $239 previously.
On August 08, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $270 to $205.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 08 ’24 when LaPlume Joseph W sold 1,780 shares for $199.36 per share. The transaction valued at 354,861 led to the insider holds 22,521 shares of the business.
Joseph LaPlume bought 1,780 shares of CRL for $350,000 on Aug 08 ’24. On Aug 01 ’24, another insider, FOSTER JAMES C, who serves as the Chairman, President and CEO of the company, sold 25,000 shares for $250.00 each. As a result, the insider received 6,250,000 and left with 188,251 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRL now has a Market Capitalization of 9959561216 and an Enterprise Value of 12671898624. As of this moment, Charles’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.80, and their Forward P/E ratio for the next fiscal year is 17.89. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.20. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.44 while its Price-to-Book (P/B) ratio in mrq is 2.67. Its current Enterprise Value per Revenue stands at 3.108 whereas that against EBITDA is 13.214.
Stock Price History:
Over the past 52 weeks, CRL has reached a high of $275.00, while it has fallen to a 52-week low of $161.65. The 50-Day Moving Average of the stock is -7.77%, while the 200-Day Moving Average is calculated to be -14.23%.
Shares Statistics:
According to the various share statistics, CRL traded on average about 678.78K shares per day over the past 3-months and 711980 shares per day over the past 10 days. A total of 51.34M shares are outstanding, with a floating share count of 51.04M. Insiders hold about 1.14% of the company’s shares, while institutions hold 102.38% stake in the company. Shares short for CRL as of 1724976000 were 1459195 with a Short Ratio of 2.78, compared to 1722384000 on 1841222. Therefore, it implies a Short% of Shares Outstanding of 1459195 and a Short% of Float of 3.66.
Earnings Estimates
The current market rating for Charles River Laboratories International Inc. (CRL) reflects the collective analysis of 15.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $2.52, with high estimates of $2.59 and low estimates of $2.42.
Analysts are recommending an EPS of between $10.08 and $9.9 for the fiscal current year, implying an average EPS of $10.01. EPS for the following year is $10.77, with 18.0 analysts recommending between $11.48 and $10.13.
Revenue Estimates
According to 13 analysts, the current quarter’s revenue is expected to be $977.71M. It ranges from a high estimate of $991.4M to a low estimate of $965.18M. As of the current estimate, Charles River Laboratories International Inc.’s year-ago sales were $1.03BFor the next quarter, 13 analysts are estimating revenue of $980.48M. There is a high estimate of $1.01B for the next quarter, whereas the lowest estimate is $970M.
A total of 16 analysts have provided revenue estimates for CRL’s current fiscal year. The highest revenue estimate was $4.04B, while the lowest revenue estimate was $3.98B, resulting in an average revenue estimate of $4B. In the same quarter a year ago, actual revenue was $4.13BBased on 16 analysts’ estimates, the company’s revenue will be $4.12B in the next fiscal year. The high estimate is $4.23B and the low estimate is $4.01B.
